# N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

> **NCT00885326** · PHASE1 · COMPLETED · sponsor: **New Approaches to Neuroblastoma Therapy Consortium** · enrollment: 29 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** cyclophosphamide
- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00885326
- **Lead sponsor:** New Approaches to Neuroblastoma Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2014-04
- **Final completion:** 2019-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00885326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00885326, "N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00885326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*